Gerald V. Doyle

15.7k citations
39 papers · 12.4k indexed · 8 hit papers · h-index 24

Impact in

  • Cancer Research top 0.05%
    • Cancer Genomics and Diagnostics
  • Oncology top 0.1%
    • Cancer Cells and Metastasis
    • Pancreatic and Hepatic Oncology Research

Papers in

    • Cancer Genomics and Diagnostics 19
    • Cancer, Hypoxia, and Metabolism 4
    • Cancer Cells and Metastasis 35

Gerald V. Doyle

39 papers receiving 12.1k citations

Hit Papers

Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500 2014 · 482 citations
482200420262011201810002.0k3.0k

Peers

Gerald V. Doyle
Comparison fields: 5 of 119
  • Cancer Research 6.8k
  • Oncology 9.6k
  • Pulmonary and Respiratory Medicine 3.7k
  • Biotechnology 630
  • Biomedical Engineering 2.9k
Replace Catherine Alix‐Panabières with:
Catherine Alix‐Panabières France
W. Jeffrey Allard United States
Jeri Matera United States
Eunice L. Kwak United States
Brian W. Brannigan United States
Sunitha Nagrath United States
Emmanuelle di Tomaso United States
Jean‐Yves Pierga France
François‐Clément Bidard France
Shannon L. Stott United States
Gerald V. Doyle relative to Catherine Alix‐Panabières France Catherine Alix‐Panabières's profile →
Citations per field
00.5×1.5×
Catherine Alix‐Panabières · 1×
Citations per year

Countries citing papers authored by Gerald V. Doyle

Since Specialization
Citations

This map shows the geographic impact of Gerald V. Doyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald V. Doyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald V. Doyle more than expected).

Fields of papers citing papers by Gerald V. Doyle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald V. Doyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald V. Doyle. The network helps show where Gerald V. Doyle may publish in the future.

Co-authors

The 25 scholars most cited alongside Gerald V. Doyle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gerald V. Doyle Line = papers co-authored together Gerald V. Doyle links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Hit paper breakdown →
20043546
2
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Hit paper breakdown →
20081744
3
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Hit paper breakdown →
20081473
4
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Hit paper breakdown →
2005857
5
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
Hit paper breakdown →
2006808
6
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer
Hit paper breakdown →
2009609
7
Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
Hit paper breakdown →
2006594
8
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Hit paper breakdown →
2014482
9 2009418
10 2007284
11 2005274
12 2005268
13 2002134
14 2001123
15 2009111
16 2005106
17 2007102
18 201381
19 200974
20 200673

About Gerald V. Doyle

Gerald V. Doyle is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Psychiatry and Mental health, having authored 39 papers that have together received 12.4k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (35 papers), Cancer Genomics and Diagnostics (19 papers), Prostate Cancer Treatment and Research (5 papers), Cancer, Hypoxia, and Metabolism (4 papers), Angiogenesis and VEGF in Cancer (4 papers), Metastasis and carcinoma case studies (4 papers), Cancer, Stress, Anesthesia, and Immune Response (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). The work is most often cited by research in Cancer Research (6.8k citations), Oncology (9.6k citations), Pulmonary and Respiratory Medicine (3.7k citations), Biotechnology (630 citations) and Biomedical Engineering (2.9k citations). Gerald V. Doyle has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Leon W.M.M. Terstappen, Michael Craig Miller, Daniel F. Hayes, Massimo Cristofanilli, Jeri Matera, G. Thomas Budd, W. Jeffrey Allard, Alison Stopeck, Matthew J. Ellis and James M. Reuben. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Research, JNCI Journal of the National Cancer Institute and International Journal of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026